nature portfolio

Corresponding author(s):	02836
Last updated by author(s):	Dec 9, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

C^{\perp}		₽.	4.4	•
\sim T	· つ	Τı	CT	ורכ

For a	Ill statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
\boxtimes	\Box The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\boxtimes	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
,	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Sof	tware and code
Polic	y information about <u>availability of computer code</u>
Da	ta collection. Provide a description of all commercial open source and custom code used to collect the data in this study, specifying the version used OR

state that no software was used.

Data analysis

Provide a description of all commercial, open source and custom code used to analyse the data in this study, specifying the version used OR state that no software was used.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Field-specific reporting				
Please select the one belo	w that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences	Behavioural & social sciences			
For a reference copy of the docum	nent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Behavioural & social sciences study design				
All studies must disclose o	n these points even when the disclosure is negative.			
Study description	Qualitative			
Research sample	National policy			
Sampling strategy	Sampling aiming for diversity of health policy approaches + pragmatic - depending on access			
Data collection	Collection of documents and interviews with experts			
Timing	2021-01-01 until 2021-10-01			
Data exclusions	Changes after 2021-10-01			
Non-participation	None			
Randomization	NA			
Reporting for specific materials, systems and methods				
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & experimental systems Methods				
n/a Involved in the study	n/a Involved in the study			
Antibodies	ChIP-seq			

Flow cytometry

MRI-based neuroimaging

Eukaryotic cell lines

Clinical data

Palaeontology and archaeology
Animals and other organisms

Human research participants

Dual use research of concern

 \boxtimes

 \boxtimes